Maxcyte (MXCT) Equity Ratio (2020 - 2025)
Maxcyte (MXCT) has disclosed Equity Ratio for 6 consecutive years, with 0.84 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio fell 1.57% to 0.84 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.84, a 1.57% decrease, with the full-year FY2024 number at 0.86, changed 0.48% from a year prior.
- Equity Ratio was 0.84 for Q3 2025 at Maxcyte, down from 0.87 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.95 in Q3 2021 to a low of 0.84 in Q3 2025.
- A 5-year average of 0.88 and a median of 0.88 in 2024 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: skyrocketed 44.2% in 2021, then dropped 6.6% in 2022.
- Maxcyte's Equity Ratio stood at 0.93 in 2021, then dropped by 4.25% to 0.89 in 2022, then fell by 2.32% to 0.87 in 2023, then dropped by 0.48% to 0.86 in 2024, then decreased by 1.95% to 0.84 in 2025.
- Per Business Quant, the three most recent readings for MXCT's Equity Ratio are 0.84 (Q3 2025), 0.87 (Q2 2025), and 0.87 (Q1 2025).